-+ 0.00%
-+ 0.00%
-+ 0.00%

Vivos Therapeutics gets Nasdaq notice for failing minimum stockholders’ equity rule

PUBT·04/22/2026 20:42:10
Listen to the news
Vivos Therapeutics gets Nasdaq notice for failing minimum stockholders’ equity rule
  • Vivos Therapeutics received Nasdaq notice on April 17, 2026 for failing to meet Listing Rule 5550(b)(1) minimum stockholders’ equity requirement.
  • Stockholders’ equity was negative USD 1.55 million as of Dec. 31, 2025, below USD 2.5 million threshold.
  • Company must submit compliance plan by June 1, 2026; Nasdaq could grant extension through Oct. 14, 2026 if plan is accepted.
  • Two first-quarter equity financings raised USD 6.8 million in gross proceeds, including a USD 4.6 million warrant exercise inducement.
  • Failure to regain compliance could trigger delisting determination; hearing request would stay delisting while Nasdaq panel reviews plan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-018562), on April 22, 2026, and is solely responsible for the information contained therein.